New bioMérieux Assay Detects Broadest Range Of HIV-1 Load Levels
This article was originally published in The Gray Sheet
Executive Summary
A "real-time" version of bioMérieux' NucliSens nucleic acid diagnostic system, the NucliSens EasyQ,will be available in the U.S. by the end of 2002, pending FDA approval of a PMA supplement, according to bioMérieux
You may also be interested in...
BioMerieux Offer For Organon Teknika Would Create $1 Bil. Diagnostics Unit
BioMerieux-Pierre Fabre's Feb. 15 offer to buy Organon Teknika's diagnostic business would increase the French company's worldwide diagnostic revenues almost 44% to roughly $0.9 bil. annually.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.